Cargando…
Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia
Ziprasidone (ZIP) shows a low propensity for metabolic side effects but can prolong QTc time. It is unclear how these features translate into clinical reality. Charts of inpatients with schizophrenia and switched from (ZIP − , n = 27) or to ZIP (ZIP + , n = 24) were reviewed. Clinical data including...
Autor principal: | Müller, Matthias J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420656/ https://www.ncbi.nlm.nih.gov/pubmed/22937263 http://dx.doi.org/10.1155/2011/317368 |
Ejemplares similares
-
The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014) -
Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine
por: Bartolommei, Natalia, et al.
Publicado: (2014) -
PM395. The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Na, Kyoungsae, et al.
Publicado: (2016) -
Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia?
por: Mattei, Chiara, et al.
Publicado: (2011) -
Ziprasidone in the Treatment of Delusional Parasitosis
por: Contreras-Ferrer, P., et al.
Publicado: (2012)